alexa Bioequivalence Of Salmeterol Xinafoate/Fluticasone Propionate HFA PMDI Of Two Different Strengths (25/250 Mcg And 25/125 Mcg Per Actuation) In Healthy Volunteers | 67135
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

8th World congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit

Muneesh Garg, Raghu Naidu, Amolkumar Birhade, Krishnan Iyer1, Ratnakar Jadhav Juliet Rebello, Nazma Morde, Mayuri Mangale and Bill Brashier
Sitec Labs Pvt. Ltd., Navi Mumbai, India
Cipla Ltd., Mumbai, India
ScientificTracks Abstracts: J Bioanal Biomed
DOI: 10.4172/1948-593X-C1-029
Abstract
Salmeterol xinafoate and fluticasone propionate has been shown to be effective and well tolerated in the treatment of asthma. The aim of these studies was to determine the bioequivalence between test and reference formulations of salmeterol xinafoate/fluticasone propionate HFA pMDI in healthy volunteers. A total of 4 pharmacokinetic studies were conducted, 2 with the higher strength (25/250 mcg per actuation) and 2 with the lower strength (25/125 mcg per actuation) of the test and reference formulation. All studies were single dose, randomized, crossover studies with a minimum washout period of 14 days. Two of the four studies (for each strength) also evaluated pulmonary deposition by blocking gastrointestinal absorption (GI) using charcoal blockade. Safety evaluations included monitoring adverse events and vital signs as well as clinical laboratory assessments. Plasma concentrations of salmeterol xinafoate and fluticasone propionate were determined using a validated LCMS/ MS method. In the studies without charcoal blockade, the 90% CI for Cmax and AUC0-t for 25/250 mcg salmeterol was 83.44-100.29, and 104.08-120.08 respectively, for 25/125 mcg it was 88.33-106.08 and 100.49-114.88 respectively. Similarly, in the studies with charcoal blockade, the 90% CI for Cmax and AUC0-t for 25/250 mcg salmeterol was 94.10-113.20, and 96.44-116.69 respectively, for 25/125 mcg it was 100.70-115.72 and 104.99-122.70 respectively. For fluticasone, the 90% CI for Cmax and AUC0-t for 25/250 mcg was 91.08-105.07 and 99.86-115.61 respectively and for 25/125 mcg, it was 87.04-105.03 and 85.38-103.42 respectively. Since the 90% CI for Cmax and AUC0-t for both salmeterol and fluticasone were within the 80–125% interval in all the studies, it was concluded that test and reference formulations of salmeterol xinafoate/fluticasone propionate HFA pMDI are bioequivalent in their rate and extent of absorption with and without charcoal blockade for both the strengths.
Biography

Muneesh Garg has completed his MD (Physician) from Dagestan State Medical Academy, Russia and MD (Pharmacology) from Government Medical College, Patiala, Punjab, India. He has more than 18 years of experience in academia, and clinical research. He is the Principal Investigator of Sitec Labs Pvt Ltd., Navi Mumbai, India, for more than 11 years and has completed about 1000 BA/BE studies. He has published many research papers in reputed journals.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7